Dynamic Biomarkers of Response to Antiangiogenic Therapies in Colorectal Cancer: A Review
- PMID: 29657584
- PMCID: PMC5872368
- DOI: 10.2174/1875692115666170815161754
Dynamic Biomarkers of Response to Antiangiogenic Therapies in Colorectal Cancer: A Review
Abstract
Background: Identification of clinical and molecular biomarkers to predict dynamic response or monitor in real-time the efficacy of antiangiogenic therapy represents a major point in the treatment of patients with advanced colorectal cancer. Several stu-dies have been conduced to identify some predictive biomarkers to select patients who will benefit from bevacizumab, the most widely used antiangiogenic monoclonal anti-body.
Conclusion: After a decade since the introduction of bevacizumab, no effective predictive biomarkers are available in routine clinical practice. In this review, we summarized the potential candidate dynamic biomarkers that may play a role in this setting.
Keywords: Colorectal cancer; angiogenesis; bevacizumab; biomarkers; chemotherapy; metastatic disease.
Similar articles
-
Markers to predict the efficacy of bevacizumab in the treatment of metastatic colorectal cancer.Tumori. 2014 Jul-Aug;100(4):370-6. doi: 10.1700/1636.17888. Tumori. 2014. PMID: 25296585 Review.
-
Use of bevacizumab in metastatic colorectal cancer: report from the Mexican opinion and analysis forum on colorectal cancer treatment with bevacizumab (September 2009).Drugs R D. 2011;11(2):101-11. doi: 10.2165/11590440-000000000-00000. Drugs R D. 2011. PMID: 21679003 Free PMC article. Review.
-
Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.BMC Cancer. 2017 Jan 9;17(1):38. doi: 10.1186/s12885-016-2994-6. BMC Cancer. 2017. PMID: 28068936 Free PMC article.
-
Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.Z Gastroenterol. 2011 Oct;49(10):1398-406. doi: 10.1055/s-0031-1281752. Epub 2011 Sep 30. Z Gastroenterol. 2011. PMID: 21964893 Review.
-
Molecular markers to predict outcome to antiangiogenic therapies in colorectal cancer: current evidence and future perspectives.Cancer Treat Rev. 2013 Dec;39(8):908-24. doi: 10.1016/j.ctrv.2013.02.004. Epub 2013 Mar 16. Cancer Treat Rev. 2013. PMID: 23510598 Review.
Cited by
-
Clinical Multigene Panel Sequencing Identifies Distinct Mutational Association Patterns in Metastatic Colorectal Cancer.Front Oncol. 2020 May 7;10:560. doi: 10.3389/fonc.2020.00560. eCollection 2020. Front Oncol. 2020. PMID: 32457828 Free PMC article.
-
Pan-immune-inflammation and its dynamics: predictors of survival and immune-related adverse events in patients with advanced NSCLC receiving immunotherapy.BMC Cancer. 2023 Oct 6;23(1):944. doi: 10.1186/s12885-023-11366-4. BMC Cancer. 2023. PMID: 37803437 Free PMC article.
-
Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC.Ther Adv Med Oncol. 2020 Aug 18;12:1758835920928635. doi: 10.1177/1758835920928635. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 32922518 Free PMC article.
-
Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers.Front Oncol. 2022 Oct 10;12:1021772. doi: 10.3389/fonc.2022.1021772. eCollection 2022. Front Oncol. 2022. PMID: 36300092 Free PMC article. Review.
References
-
- International Agency for Research on Cancer 2015 http://globocan.iarc.fr/Pages/fact_sheets_
-
- Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev. 1997;18:4–25. - PubMed
-
- Lee J.C., Chow N.H., Wang S.T., et al. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur. J. Cancer. 2000;36:748–753. - PubMed
-
- Giantonio B.J., Levy D.E., O’dwyer P.J., et al. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: Results from the Eastern cooperative oncology group study E2200. Ann. Oncol. 2006;17:1399–1403. - PubMed
-
- Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J. Mol. Med. (Berl.) 1999;77:527–543. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources